Free Trial

Y-mAbs Therapeutics (YMAB) Competitors

Y-mAbs Therapeutics logo
$4.35 +0.13 (+3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$4.33 -0.02 (-0.55%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

YMAB vs. IMNM, SNDX, KALV, REPL, XERS, VIR, PHAR, GYRE, NUVB, and SANA

Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Immunome (IMNM), Syndax Pharmaceuticals (SNDX), KalVista Pharmaceuticals (KALV), Replimune Group (REPL), Xeris Biopharma (XERS), Vir Biotechnology (VIR), Pharming Group (PHAR), Gyre Therapeutics (GYRE), Nuvation Bio (NUVB), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

Y-mAbs Therapeutics vs. Its Competitors

Immunome (NASDAQ:IMNM) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

In the previous week, Immunome had 4 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 5 mentions for Immunome and 1 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 1.87 beat Immunome's score of 1.41 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Immunome Positive
Y-mAbs Therapeutics Very Positive

Y-mAbs Therapeutics has a net margin of -31.84% compared to Immunome's net margin of -1,875.21%. Y-mAbs Therapeutics' return on equity of -30.59% beat Immunome's return on equity.

Company Net Margins Return on Equity Return on Assets
Immunome-1,875.21% -71.65% -60.36%
Y-mAbs Therapeutics -31.84%-30.59%-22.70%

Y-mAbs Therapeutics has higher revenue and earnings than Immunome. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immunome$9.04M93.07-$292.96M-$3.18-3.04
Y-mAbs Therapeutics$87.68M2.25-$29.67M-$0.64-6.80

Immunome currently has a consensus target price of $23.33, suggesting a potential upside of 141.30%. Y-mAbs Therapeutics has a consensus target price of $15.60, suggesting a potential upside of 258.62%. Given Y-mAbs Therapeutics' higher possible upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Immunome.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunome
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Y-mAbs Therapeutics
2 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.82

Immunome has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 8.6% of Immunome shares are owned by company insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Y-mAbs Therapeutics beats Immunome on 12 of the 17 factors compared between the two stocks.

Get Y-mAbs Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YMAB vs. The Competition

MetricY-mAbs TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$191.10M$2.91B$5.52B$9.32B
Dividend YieldN/A2.46%3.76%4.05%
P/E Ratio-6.807.7720.1819.43
Price / Sales2.25300.75437.3299.95
Price / CashN/A42.3835.5357.53
Price / Book2.127.768.235.67
Net Income-$29.67M-$55.11M$3.23B$257.51M
7 Day Performance-2.03%0.95%-0.01%0.52%
1 Month Performance-11.94%8.44%5.61%8.84%
1 Year Performance-66.74%-2.38%26.52%14.18%

Y-mAbs Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
YMAB
Y-mAbs Therapeutics
4.1598 of 5 stars
$4.35
+3.1%
$15.60
+258.6%
-67.5%$191.10M$87.68M-6.80150Positive News
IMNM
Immunome
2.1471 of 5 stars
$8.69
-1.7%
$23.33
+168.5%
-40.7%$756.12M$9.04M-2.7340News Coverage
Positive News
Gap Up
SNDX
Syndax Pharmaceuticals
3.0742 of 5 stars
$8.73
-3.0%
$35.80
+310.1%
-62.2%$751.22M$23.68M-2.26110News Coverage
Analyst Forecast
KALV
KalVista Pharmaceuticals
4.0395 of 5 stars
$15.06
+25.7%
$24.14
+60.3%
+1.4%$748.78MN/A-4.05100Earnings Report
Analyst Revision
High Trading Volume
REPL
Replimune Group
4.1221 of 5 stars
$9.65
+2.7%
$20.83
+115.9%
+14.7%$743.92MN/A-3.14210News Coverage
Analyst Forecast
Options Volume
Gap Up
High Trading Volume
XERS
Xeris Biopharma
3.9394 of 5 stars
$4.70
-1.1%
$6.25
+33.0%
+113.3%$734.99M$203.07M-15.67290News Coverage
VIR
Vir Biotechnology
3.5707 of 5 stars
$5.27
-2.6%
$32.86
+523.5%
-44.6%$728.51M$14.30M-1.25580
PHAR
Pharming Group
2.079 of 5 stars
$10.47
-1.0%
$30.00
+186.5%
+16.0%$719.77M$320.71M-52.35280Gap Down
GYRE
Gyre Therapeutics
0.1257 of 5 stars
$7.62
-6.3%
N/A-48.7%$714.45M$105.76M381.1940News Coverage
NUVB
Nuvation Bio
3.128 of 5 stars
$2.08
-0.5%
$7.17
+244.6%
-37.9%$707.75M$10.96M-0.8960High Trading Volume
SANA
Sana Biotechnology
3.2386 of 5 stars
$3.10
-2.8%
$9.17
+195.7%
-34.3%$698.98MN/A-3.52380

Related Companies and Tools


This page (NASDAQ:YMAB) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners